Clinical Trials Logo

Cardioversion clinical trials

View clinical trials related to Cardioversion.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04468321 Active, not recruiting - Atrial Fibrillation Clinical Trials

Heart Watch Study: a Pragmatic Randomized Controlled Trial

Start date: August 18, 2021
Phase: N/A
Study type: Interventional

This will be a prospective multi-center, randomized, controlled trial of 150 patients conducted to assess the impact of individual use of the Apple Watch compared to the Withings Move on patient-reported and clinical outcomes at 6 months and up to 1 year.

NCT ID: NCT01924065 Active, not recruiting - Atrial Fibrillation Clinical Trials

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

AFTER-CV
Start date: August 2013
Phase: Phase 3
Study type: Interventional

Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between 2.0-3.0. Those who do not want to use warfarin will be given an approved new oral anticoagulant agent istead of warfarin for 3 weeks. If thrombus is detected in left atrium or in left atrial appendage, no cardioversion will be performed. Other patients in the both groups will undergo electrical cardioversion. After the procedures all the patients will be given oral anticoagulant for at least 4 Weeks. All patients will have neurological examination and diffusion magnetic resonance imaging (MRI) at baseline and at postprocedural 7th day. Clinical and subclinical cerebral thromboembolic events detected by diffusion MRI will be recorded. Any bleeding events will also be recorded.